NCT04239976View on ClinicalTrials.gov

Scrambler Therapy for the Reduction of Chemotherapy-Induced Neuropathic Pain

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

March 18, 2022

Study Completion Date

March 18, 2022

Conditions
Chemotherapy-Induced Peripheral NeuropathyMalignant Neoplasm
Interventions
DEVICE

FitBit

Wear FitBit for gait assessment test

OTHER

Gait Assessment Test

Undergo gait assessment test

OTHER

MC5-A Scrambler Therapy

Undergo scrambler therapy

OTHER

Quality-of-Life Assessment

Ancillary studies

PROCEDURE

Quantitative Sensory Testing

Undergo quantitative sensory test

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT04239976 - Scrambler Therapy for the Reduction of Chemotherapy-Induced Neuropathic Pain | Biotech Hunter | Biotech Hunter